Impact of thimerosal-related changes in hepatitis B vaccine birth-dose recommendations on childhood vaccination coverage

JAMA

Volumn 291, Issue 19, 2004, Pages 2351-2358

  Luman, Elizabeth T ^a,c   Fiore, Anthony E ^b   Strine, Tara W ^a,d   Barker, Lawrence E ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c EMORY UNIVERSITY   (United States)

^d NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; MERCURY; THIOMERSAL; PRESERVATIVE;

ARTICLE; CHILDHOOD DISEASE; COHORT ANALYSIS; DOSE TIME EFFECT RELATION; DRUG SAFETY; HUMAN; IMMUNIZATION; INFANT; INFANT DISEASE; MAJOR CLINICAL STUDY; MERCURIALISM; NEWBORN CARE; PRIORITY JOURNAL; PUBLIC HEALTH; STATISTICAL SIGNIFICANCE; TRUST; UNITED STATES; VACCINATION; HEALTH SURVEY; NEWBORN; PRACTICE GUIDELINE; STANDARD; UTILIZATION REVIEW;

COHORT STUDIES; HEALTH SURVEYS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; PRACTICE GUIDELINES; PRESERVATIVES, PHARMACEUTICAL; THIMEROSAL; UNITED STATES; VACCINATION;

EID: 2442613899     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.19.2351     Document Type: Article

References (54)

1. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR-13):1-25.
2. Yusuf HR, Daniels D, Smith P, Coronado V, Rodewald L. Association between administration of hepatitis B vaccine at birth and completion of the hepatitis B and 4:3:1:3 vaccine series. JAMA. 2000;284:978-983.
3. Lauderdale DS, Oram RJ, Goldstein KP, Daum RS. Hepatitis B vaccination among children in inner-city public housing, 1991-1997. JAMA. 1999;282:1725-1730.
4. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics. 2001; 107:1147-1154.
5. Stratton K, Gable A, McCormick MC, eds. Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders. Washington, DC: National Academy Press; 2001.
6. Freed GL, Andreae MC, Cowan AE, Katz SL. The process of public policy formulation: the case of thimerosal in vaccines. Pediatrics. 2002;109:1153-1159.
7. Centers for Disease Control and Prevention. Notice to readers: thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR Morb Mortal Wkly Rep. 1999;48:563-565.
8. Centers for Disease Control and Prevention. Notice to readers: availability of hepatitis B vaccine that does not contain thimerosal as a preservative. MMWR Morb Mortal Wkly Rep. 1999;48:780-782.
9. Centers for Disease Control and Prevention. Recommendations regarding the use of vaccines that contain thimerosal as a preservative. MMWR Morb Mortal Wkly Rep. 1999;48:996-998.
10. Centers for Disease Control and Prevention. Impact of the 1999 AAP/USPHS joint statement on thimerosal in vaccines on infant hepatitis B vaccination practices. MMWR Morb Mortal Wkly Rep. 2001;50: 94-97.
11. Oram RJ, Daum RS, Seal JB, Lauderdale DS. Impact of recommendations to suspend the birth dose of hepatitis B virus vaccine. JAMA. 2001;285:1874-1879.
12. Clark SJ, Cabana MD, Malik T, Yusuf H, Freed GL. Hepatitis B vaccination practices in hospital newborn nurseries before and after changes in vaccination recommendations. Arch Pediatr Adolesc Med. 2001;155: 915-920.
13. Hurie MB, Saari TN, Davis JP. Impact of the joint statement by the American Academy of Pediatrics/US Public Health Service on thimerosal in vaccines on hospital infant hepatitis B vaccination practices. Pediatrics. 2001;107:755-758.
14. Brayden RM, Pearson KA, Jones JS, Renfrew BL, Berman S. Effect of thimerosal recommendations on hospitals' neonatal hepatitis B vaccination policies. J Pediatr. 2001;138:752-755.
15. State and national vaccination coverage levels among children aged 19-35 months-United States, April-December 1994. MMWR Morb Mortal Wkly Rep. 1995;44:613, 619, 621-623.
16. Centers for Disease Control and Prevention. National, state and urban area vaccination coverage levels among children aged 19-35 months-United States, January-December 1995. MMWR Morb Mortal Wkly Rep. 1997;46:176-182.
17. Centers for Disease Control and Prevention. Vaccination coverage by race/ethnicity and poverty status-United States, 1996. MMWR Morb Mortal Wkly Rep. 1997;46:963-968.
18. Centers for Disease Control and Prevention. National, state and urban area vaccination coverage levels among children aged 19-35 months-United States, 1997. MMWR Morb Mortal Wkly Rep. 1998;47:547-554.
19. Centers for Disease Control and Prevention. Notice to readers: national vaccination coverage levels among children aged 19-35 months-United States, 1998. MMWR Morb Mortal Wkly Rep. 1999;48:829-830.
20. Centers for Disease Control and Prevention. National, state and urban area vaccination coverage levels among children aged 19-35 months-United States, January-December 1999. MMWR Morb Mortal Wkly Rep. 2000;49:585-589.
21. Centers for Disease Control and Prevention. National, state and urban area vaccination coverage levels among children aged 19-35 months-United States, 2000. MMWR Morb Mortal Wkly Rep. 2001;50:637-641.
22. Barker L, Luman E, Zhao Z, Smith P, Linkins R, Santoli J, Rodewald L, McCauley M. National, state, and urban area vaccination coverage levels among children aged 19-35 months-United States, 2001. MMWR Morb Mortal Wkly Rep. 2002;51:664-666.
23. Smith PJ, Battaglia MP, Huggins VJ, et al. Overview of the sampling design and statistical methods used in the National Immunization Survey. Am J Prev Med. 2001;20(suppl 4):17-24.
24. Zell E, Ezzati-Rice TM, Battaglia M, Wright R. National Immunization Survey: the methodology of a vaccination surveillance system. Public Health Rep. 2000; 115:65-77.
25. Frankel MR, Srinath KP, Hoaglin DC, et al. Adjustments for non-telephone bias in random-digit-dialling surveys. Stat Med. 2003;22:1611-1626.
26. Smith PJ, Rao JNK, Battaglia MP, et al. Compensating for Provider Nonresponse Using Response Propensities to Form Adjustment Cells: The National Immunization Survey. Hyattsville, Md: National Center for Health Statistics; 2001. Vital and Health Statistics Series 2, No. 133.
27. Centers for Disease Control and Prevention. Recommended Childhood Immunization Schedule-United States, January-June 1996. MMWR Morb Mortal Wkly Rep. 1996;44:940-943.
28. Centers for Disease Control and Prevention. Recommended Childhood Immunization Schedule-United States, 2001. MMWR Morb Mortal Wkly Rep. 2001;50:7-10, 19.
29. Dalaker J. Poverty in the United States, 1998. Washington, DC: US Government Printing Office; 1999. Current Population Report, Series P60-207.
30. Stokley S, Smith PJ, Klevens RM, Battaglia MP. Vaccination status of children living in rural areas in the United States: are they protected? Am J Prev Med. 2001;20(suppl 4):55-60.
31. US Census Bureau. Census 2000 Basics. Washington, DC: US Government Printing Office; 2002.
32. Research Triangle Institute. SUDAAN User's Manual, Release 8.0. Research Triangle Park, NC: Research Triangle Institute; 2001.
33. Centers for Disease Control and Prevention. Vital Statistics of the United States, 1999, Volume 1, Natality. Hyattsville, Md: National Center for Health Statistics; 2001.
34. Centers for Disease Control and Prevention. Hepatitis Surveillance Report. Atlanta, Ga: Centers for Disease Control and Prevention; 1996. No. 56.
35. Centers for Disease Control and Prevention. Guidelines for Viral Hepatitis Surveillance and Case Management. Atlanta, Ga: Centers for Disease Control and Prevention; 2002.
36. McMahon BJ, Alward WLM, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151:599-603.
37. Beasley RP, Hwang L-Y. Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral Hepatitis and Liver Disease. New York, NY: Grune & Stratton; 1984:209-224.
38. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA. 1995;274:1201-1208.
39. Armstrong GL, Mast EE, Wojczynski M, Margolis HS. Childhood hepatitis B virus infections in the United States before hepatitis B immunization. Pediatrics. 2001;108:1123-1128.
40. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc R Soc Lond B Biol Sci. 1993;253:197-201.
41. Ventura SJ, Martin JA, Curtin SC, Menacker F, Hamilton BE. Births: final data for 1999. Natl Vital Stat Rep. 2001;49:1-100.
42. Martin JA, Hamilton BE, Ventura SJ, Menacker F, Park MM. Births: final data for 2000. Natl Vital Stat Rep. 2002;50:1-101.
43. Cabana MD, Aiken KD, Davis MM, et al. Effect of state vaccine-financing strategy on hepatitis B immunization in hospital nurseries. Ambul Pediatr. 2002; 2:367-374.
44. Cooper A, Yusuf H, Rodewald L, Malik T, Pollard R, Pickering L. Attitudes, practices, and preferences of pediatricians regarding initiation of hepatitis B immunization at birth. Pediatrics. 2001;108:e98.
45. Centers for Disease Control and Prevention. Notice to readers: FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants. MMWR Morb Mortal Wkly Rep. 2003;52:203-204.
46. Biroscak BJ, Fiore AE, Fasano N, et al. Impact of the thimerosall controversy on hepatitis B vaccine coverage of infants born to women of unknown hepatitis B surface antigen status in Michigan. Pediatrics. 2003;1.11:e645-e649.
47. Madsen KM, Lauritsen MB, Pedersen CB, et al. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics. 2003;112:604-606.
48. Clarkson TW, Magos L, Myers GJ. The toxicology of mercury-current exposures and clinical manifestations. N Engl J Med. 2003;349:1731-1737.
49. Pichichero ME, Cernichiari E, Lopricato J, Treanor J. Mercury concentrations and metabolism in infants reciving vaccines containing thimerosal: a descriptive study. Lancet. 2002;360:1737-1741.
50. Verstraeten T, Davis RL, DeStefano F, et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics. 2003;112:1039-1048.
51. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351:637-641.
52. DeStefano F, Thompson WW. MMR vaccine and autism: an update of the scientific evidence. Expert Rev Vaccines. 2004;3:19-22.
53. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. MMWR Morb Mortal Wkly Rep. 1999;48:577-581.
54. Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep. 1999;48:1007.